Poly(ethylene glycol) induces cell toxicity in melanoma cells by producing a hyperosmotic extracellular medium
Source abstract
Abstract
Poly(ethylene glycol) is a polymer that is widely used as a biomaterial and has been approved in a host of applications. While generally viewed as inert, recent studies with poly(ethylene glycol) suggest that it may have some effects on cells and tissues, making it potentially attractive as a therapeutic agent. In this study, the effect of poly(ethylene glycol) on the cell viability, membrane transport and apoptotic markers of metastatic melanoma cells was examined. The data were combined with observed effects of the polymer on the cell media, including osmolality and viscosity, in order to elucidate any structure-function relationship between the polymer and cells. It was observed that poly(ethylene glycol) reduced the cellular viability of A375 cells, and that the effect was dependent on poly(ethylene glycol) molecular weight and concentration. The mechanism was highly correlated with changes in the osmolality of the cell medium, which is determined by the inherent structure of poly(ethylene glycol), and in particular the ethylene oxide units. This mechanism was specific to poly(ethylene glycol) and was not observed with the similar linear, hydrophilic polymer poly(vinyl pyrrolidone). Overall, the data suggest that poly(ethylene glycol) and poly(ethylene glycol)-like compounds have a distinct effect on cellular activity, presumably mediated in part by their osmotic effects, supporting the further investigation of these polymers as pharmaceutically active compounds.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Polymer Surface Interaction Studies · Dendrimers and Hyperbranched Polymers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
McMaster University, Hamilton, Ontario, Canada
Funding
Natural Sciences and Engineering Research Council of Canada
References (52)
Show source-provided references
1. 10.1007/12_02010.1007/12_020 ↗
2. 10.1016/j.jconrel.2015.09.04310.1016/j.jconrel.2015.09.043 ↗
3. Sanofi Aventis. “Renvela (sevelamer carbonate) Product Monograph,” 2017.
4. Sanofi Aventis. “Sodium Polystyrene Sulfonate Product Monograph,”2014.
5. Valeant. “Colesevelam hydrochloride Product Mono-graph.” 2014.
6. 10.1086/37399610.1086/373996 ↗
7. 10.1021/bc060042y10.1021/bc060042y ↗
8. 10.1021/ja953729u10.1021/ja953729u ↗
9. 10.1021/mp500298q10.1021/mp500298q ↗
10. 10.4049/jimmunol.130034510.4049/jimmunol.1300345 ↗
11. 10.1002/1097-4636(20000905)51:3<343::AID-JBM7>3.0.CO;2-D10.1002/1097-4636(20000905)51:3<343::AID-JBM7>3.0.CO;2-D ↗
12. 10.1016/j.xphs.2015.11.01510.1016/j.xphs.2015.11.015 ↗
13. 10.1016/j.biomaterials.2010.02.04410.1016/j.biomaterials.2010.02.044 ↗
14. 10.1080/17425247.2016.118248510.1080/17425247.2016.1182485 ↗
15. 10.1016/j.jconrel.2008.04.01310.1016/j.jconrel.2008.04.013 ↗
16. 10.1073/pnas.101161410710.1073/pnas.1011614107 ↗
17. 10.1016/0014-5793(94)01023-410.1016/0014-5793(94)01023-4 ↗
18. 10.1016/S0014-5793(01)02420-610.1016/S0014-5793(01)02420-6 ↗
19. 10.1158/1535-7163.MCT-08-043410.1158/1535-7163.MCT-08-0434 ↗
20. 10.1002/jps.1017510.1002/jps.10175 ↗
21. 10.1002/jps.1026510.1002/jps.10265 ↗
22. 10.1208/ps04044010.1208/ps040440 ↗
23. 10.1023/A:101603370222010.1023/A:1016033702220 ↗
24. Mountfield RJ · J Pharm · 2000 · 211 · 89
25. 10.1021/ma60011a01510.1021/ma60011a015 ↗
26. 10.1016/0032-3861(75)90008-710.1016/0032-3861(75)90008-7 ↗
27. 10.1038/nrd108810.1038/nrd1088 ↗
28. 10.1016/S1359-6446(05)03575-010.1016/S1359-6446(05)03575-0 ↗
29. 10.1073/pnas.94.16.837810.1073/pnas.94.16.8378 ↗
30. 10.1021/bk-1997-068010.1021/bk-1997-0680 ↗
31. 10.1016/S1521-690X(03)00049-610.1016/S1521-690X(03)00049-6 ↗
32. 10.1371/journal.pone.007655010.1371/journal.pone.0076550 ↗
33. 10.1016/j.soc.2010.09.00710.1016/j.soc.2010.09.007 ↗
34. 10.1038/sj.leu.240143810.1038/sj.leu.2401438 ↗
35. 10.1111/j.1432-1033.1992.tb17083.x10.1111/j.1432-1033.1992.tb17083.x ↗
36. National Cancer Institute. “Drugs Approved for Melanoma,” [Online], https://www.cancer.gov/about-cancer/treatment/drugs/melanoma (2018, accessed 16 September 2018).
37. 10.1111/j.1742-4658.2007.06140.x10.1111/j.1742-4658.2007.06140.x ↗
38. ATCC. “A-375 ATCC-CRL-1619™ Homo sapiens skin malignant melanoma cells. Manassas, Virginia, USA.”
39. 10.1021/j100170a06010.1021/j100170a060 ↗
40. 10.1021/j100299a02110.1021/j100299a021 ↗
41. Sundquist T · 2006 · 16 · 18
42. Ahmed N. · 201610.1093/hesc/9780199674442.001.0001 ↗
43. Shukla A · DNA Repair (Amst) · 2004 · 21 · 391
44. Argyropoulos C · Cureus · 2016 · 8 · e596
45. 10.1042/bj357013710.1042/bj3570137 ↗
46. 10.1016/0016-5085(88)90550-110.1016/0016-5085(88)90550-1 ↗
47. Lang F · Compr Physiol · 2012 · 2 · 203710.1002/cphy.c110046 ↗
48. 10.1016/j.febslet.2006.10.07410.1016/j.febslet.2006.10.074 ↗
49. 10.1242/jcs.01734310.1242/jcs.017343 ↗
50. Vlak JM. · 1996
51. 10.1098/rstb.2013.010910.1098/rstb.2013.0109 ↗
52. 10.1002/anie.20090267210.1002/anie.200902672 ↗